A phase I study of Calmangafodipir (PledOx) in Japanese and Caucasian Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Calmangafodipir (Primary)
- Indications Chemotherapy-induced damage; Liver failure
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SUNCIST
- 01 Dec 2017 According to a PledPharma AB media release, first set of patients have been enrolled in the study and the data form this trial will be used for an expansion of the phase III clinical program, aims to include Asian patients.
- 01 Dec 2017 Status changed from planning to recruiting, according to a PledPharma AB media release.
- 24 Nov 2017 New trial record